{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T17:50:54Z","timestamp":1777139454964,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40123-016-0057-3","type":"journal-article","created":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T07:25:42Z","timestamp":1470295542000},"page":"191-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prospective Observational Post-marketing Study of Tafluprost 0.0015%\/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety"],"prefix":"10.1007","volume":"5","author":[{"given":"Yasutaka","family":"Takagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Kai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,4]]},"reference":[{"key":"57_CR1","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.survophthal.2008.08.002","volume":"53","author":"GF Schwartz","year":"2008","unstructured":"Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53:S57\u201368.","journal-title":"Surv Ophthalmol"},{"key":"57_CR2","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/archopht.126.5.718","volume":"126","author":"MS Juzych","year":"2008","unstructured":"Juzych MS, Randhawa S, Shukairy A, et al. Functional health literacy in patients with glaucoma in urban settings. Arch Ophthalmol. 2008;126:718\u201324.","journal-title":"Arch Ophthalmol"},{"key":"57_CR3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0161-6420(02)01974-7","volume":"110","author":"PP Chen","year":"2003","unstructured":"Chen PP. Blindness in patients with treated open-angle glaucoma. Ophthalmology. 2003;110:726\u201333.","journal-title":"Ophthalmology"},{"key":"57_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002512-200522010-00001","volume":"22","author":"RE Marquis","year":"2005","unstructured":"Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging. 2005;22:1\u201321.","journal-title":"Drugs Aging"},{"key":"57_CR5","volume-title":"Terminology and guidelines for glaucoma","author":"European Glaucoma Society","year":"2014","unstructured":"European Glaucoma Society. Terminology and guidelines for glaucoma. 4th ed. Savona: PubliComm; 2014.","edition":"4"},{"key":"57_CR6","first-page":"1185","volume":"30","author":"Y Kuwayama","year":"2013","unstructured":"Kuwayama Y, DE-111 Collaborative Trial Group. Phase III double-masked study of fixed combination tafluprost 0.0015%\/timolol 0.5% (DE-111) versus tafluprost 0.0015% alone or given concomitantly with timolol 0.5% in primary open angle glaucoma and ocular hypertension. Atarasii Gannka (J Eye). 2013;30:1185\u201394 (in Japanese).","journal-title":"Atarasii Gannka (J Eye)"},{"key":"57_CR7","first-page":"1773","volume":"30","author":"Y Kuwayama","year":"2013","unstructured":"Kuwayama Y, DE-111 Collaborative Trial Group. Phase III double-masked study of fixed combination tafluprost 0.0015%\/timolol 0.5% (DE-111) versus timolol 0.5% ophthalmic solution in primary open-angle glaucoma and ocular hypertension. Atarasii Gannka (J Eye). 2013;30:1773\u201381 (in Japanese).","journal-title":"Atarasii Gannka (J Eye)"},{"key":"57_CR8","first-page":"1641","volume":"111","author":"A Iwase","year":"2004","unstructured":"Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi study. Ophthalmology. 2004;111:1641\u20138.","journal-title":"Ophthalmology"},{"key":"57_CR9","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ophtha.2005.05.012","volume":"112","author":"T Yamamoto","year":"2005","unstructured":"Yamamoto T, Iwase A, Araie M, Suzuki Y, Abe H, Shirato S, et al. The Tajimi study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology. 2005;112:1661\u20139.","journal-title":"Ophthalmology"},{"key":"57_CR10","first-page":"573","volume":"68","author":"A Yoshida","year":"2014","unstructured":"Yoshida A, Morimasa M, Bando E, Watanabe T, Komatsubara A, Endo Y. An interim report of the safety and efficacy of latanoprost and timolol maleate (Xalacom\u00ae combination ophthalmic solution). Rinsho Ganka (Jpn J Clin Ophthalmol). 2014;68:573\u201380 in Japanese.","journal-title":"Rinsho Ganka (Jpn J Clin Ophthalmol)"},{"key":"57_CR11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10384-005-0293-x","volume":"50","author":"Y Ikeda","year":"2006","unstructured":"Ikeda Y, Mori K, Ishibashi T, Naruse S, Nakajima N, Kinoshita S. Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jpn J Ophthalmol. 2006;50:153\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"57_CR12","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00061198-200312000-00004","volume":"12","author":"CB Camras","year":"2003","unstructured":"Camras CB, Hedman K, US Latanoprost Study Group. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma. 2003;12:466\u20139.","journal-title":"J Glaucoma"},{"key":"57_CR13","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2147\/OPTH.S33414","volume":"6","author":"T Mizoguchi","year":"2012","unstructured":"Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M. A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma. Clin Ophthalmol. 2012;6:1579\u201384.","journal-title":"Clin Ophthalmol"},{"key":"57_CR14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0161-6420(02)01891-2","volume":"110","author":"SA Gandolfi","year":"2003","unstructured":"Gandolfi SA, Cimono L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 2003;110:609\u201314.","journal-title":"Ophthalmology"},{"key":"57_CR15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF02853173","volume":"19","author":"RD Williams","year":"2002","unstructured":"Williams RD. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther. 2002;19:275\u201381.","journal-title":"Adv Ther"},{"key":"57_CR16","first-page":"1761","volume":"30","author":"K Ueda","year":"2013","unstructured":"Ueda K, Tonouchi A, Fukano Y, Asada H, Kawazu K. Tafluprost 0.0015%\/timolol 0.5% combination ophthalmic solution (DE-111 ophthalmic solution) formulation design and intraocular penetration in rats. Atarashii Ganka (J Eye). 2013;30:1761\u20136 (in Japanese).","journal-title":"Atarashii Ganka (J Eye)"},{"key":"57_CR17","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Bebgtsson B, Hussein M, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120:1268\u201379.","journal-title":"Arch Ophthalmol"},{"key":"57_CR18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajo.2004.04.022","volume":"138","author":"JH Liu","year":"2004","unstructured":"Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138:389\u201395.","journal-title":"Am J Ophthalmol"},{"key":"57_CR19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/112067210801800110","volume":"18","author":"T Takmaz","year":"2008","unstructured":"Takmaz T, A\u015fik S, K\u00fcrk\u00e7\u00fco\u011flu P, Gurdal C, Can I. Comparison of intraocular pressure lowering effect of once daily morning vs evening dosing of latanoprost\/timolol maleate combination. Eur J Ophthalmol. 2008;18:60\u20135.","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"57_CR20","first-page":"455","volume":"33","author":"N Takeda","year":"2016","unstructured":"Takeda N, Udagawa S, Higashide T, Ohkubo S, Takemoto Y, Sugiyama K. Comparison of intraocular pressure-reducing effect of morning vs. evening dosing of latanoprost and timolol. Atarasii Ganka (J Eye). 2016;33(3):455\u20139 (in Japanese).","journal-title":"Atarasii Ganka (J Eye)"},{"key":"57_CR21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1755-3768.2007.01145.x","volume":"87","author":"AG Konstas","year":"2009","unstructured":"Konstas AG, Tsironi S, Vakalis AN, Nasr MB, Stewart JA, Nelson LA, et al. Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. Acta Ophthalmol. 2009;87:71\u20136.","journal-title":"Acta Ophthalmol"},{"key":"57_CR22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/IJG.0b013e3181815421","volume":"18","author":"F Djafari","year":"2009","unstructured":"Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18:238\u201343.","journal-title":"J Glaucoma"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-016-0057-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:38:07Z","timestamp":1568248687000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40123-016-0057-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["57"],"URL":"https:\/\/doi.org\/10.1007\/s40123-016-0057-3","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,4]]}}}